Show simple item record

dc.contributor.authorKaialy, Waseem
dc.contributor.authorNokhodchi, Ali
dc.date.accessioned2015-08-25T13:59:01Zen
dc.date.available2015-08-25T13:59:01Zen
dc.date.issued2013-05-01
dc.identifier.citationTreating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs. 2013, 448 (1):58-70 Int J Pharm
dc.identifier.issn1873-3476
dc.identifier.pmid23500603
dc.identifier.doi10.1016/j.ijpharm.2013.03.005
dc.identifier.urihttp://hdl.handle.net/2436/575955
dc.description.abstractThe aim of this study was to evaluate the influence of treatment of a promising dry powder aerosol carrier (mannitol) on the aerosolization performance of salbutamol sulphate (SS) using a novel approach: treating excess commercial carrier particles in a saturated solution of the same carrier. Commercial mannitol (CM) particles were treated with aqueous mannitol supersaturated solutions (20% and 25% w/v), under stirring, (300 rpm) for either 24h or 48 h. The results showed that particle treatment did not alter the polymorphic form of mannitol (β-mannitol); however, all treated mannitol particles demonstrated smoother surface topography and improved aerosolization performance compared to CM in dry powder inhalations. Unlike the concentration of mannitol solution used during treatment, the time of treatment to collect mannitol crystals was an essential key to modify the physical properties of mannitol and its effect on the aerosolization performance. In comparison to mannitol particles treated for 48 h, mannitol particles treated for 24h demonstrated larger size, more elongated-less regular shape, and smoother surfaces. No apparent relationship was obtained between in vitro aerosolisation behavior of SS with either mannitol particle size or shape descriptors. However, despite their larger size and more irregular-less uniformed shape, treated mannitol particles with smoother surfaces generated drug particles with smaller aerodynamic size and are expected to deliver higher amounts of drug to lower airways. The results demonstrated the potential of treating mannitol particles in aqueous solutions of the same material under controlled conditions to produce mannitol particles promising for dry powder inhaler systems. The results suggested that mannitol particle surface texture properties dominate over both particle size and particle shape of mannitol in terms of determining the aerosolization performance of mannitol.
dc.language.isoen
dc.publisherElsevier
dc.subjectDry powder inhaler
dc.subjectMannitol
dc.subjectSurface roughness
dc.subjectAgglomeration
dc.subjectAggregation
dc.subject.meshAdministration, Inhalation
dc.subject.meshAerosols
dc.subject.meshAlbuterol
dc.subject.meshCalorimetry, Differential Scanning
dc.subject.meshCrystallization
dc.subject.meshDrug Delivery Systems
dc.subject.meshLung
dc.subject.meshMannitol
dc.subject.meshMicroscopy, Atomic Force
dc.subject.meshMicroscopy, Electron, Scanning
dc.subject.meshParticle Size
dc.subject.meshPowders
dc.subject.meshSpectroscopy, Fourier Transform Infrared
dc.titleTreating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs.
dc.typeJournal article
dc.identifier.journalInternational journal of pharmaceutics
html.description.abstractThe aim of this study was to evaluate the influence of treatment of a promising dry powder aerosol carrier (mannitol) on the aerosolization performance of salbutamol sulphate (SS) using a novel approach: treating excess commercial carrier particles in a saturated solution of the same carrier. Commercial mannitol (CM) particles were treated with aqueous mannitol supersaturated solutions (20% and 25% w/v), under stirring, (300 rpm) for either 24h or 48 h. The results showed that particle treatment did not alter the polymorphic form of mannitol (β-mannitol); however, all treated mannitol particles demonstrated smoother surface topography and improved aerosolization performance compared to CM in dry powder inhalations. Unlike the concentration of mannitol solution used during treatment, the time of treatment to collect mannitol crystals was an essential key to modify the physical properties of mannitol and its effect on the aerosolization performance. In comparison to mannitol particles treated for 48 h, mannitol particles treated for 24h demonstrated larger size, more elongated-less regular shape, and smoother surfaces. No apparent relationship was obtained between in vitro aerosolisation behavior of SS with either mannitol particle size or shape descriptors. However, despite their larger size and more irregular-less uniformed shape, treated mannitol particles with smoother surfaces generated drug particles with smaller aerodynamic size and are expected to deliver higher amounts of drug to lower airways. The results demonstrated the potential of treating mannitol particles in aqueous solutions of the same material under controlled conditions to produce mannitol particles promising for dry powder inhaler systems. The results suggested that mannitol particle surface texture properties dominate over both particle size and particle shape of mannitol in terms of determining the aerosolization performance of mannitol.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record